A2i Therapeutics

Novel Small-molecule Immuno-oncology Agents

Startup

A2i Therapeutics is a -based startup in the Health Tech & Life Sciences sector, established in 2020. Novel Small-molecule Immuno-oncology Agents. Key investors include RMGP Biopharma Investment Fund, FutuRx. The company has 1-10 employees. Core technologies: Biologicals, Molecules.

The company follows a B2B business model. Product stage: R&D.

2
Rounds
2
Investors
1
Team
2020
Founded
Sector & Technology
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentBiologicalsMolecules
At a Glance
Investors
In the News

1 article covered by sources including www.businesswire.com.

www.businesswire.com · Dec 20, 2020
Atomwise and FutuRx Launch A2i Therapeutics - A New Immuno-Oncology Company Funded By Leading Biopharma VCs and the Israeli Innovation Authority
Read article ↗
Frequently Asked Questions
What does A2i Therapeutics do?

A2i Therapeutics is developing novel small-molecule immuno-oncology agents. The company was formed as a joint venture between FutuRx, an Israeli-based biotechnology incubator focused on innovative, early-stage therapeutic technologies, and Atomwise, a US-based company using artificial intelligence for small-molecule drug discovery. The partnership will leverage Atomwise's AI platform to target a key protein involved in controlling the innate immune response and potentially a key immuno-oncology target.

What sector is A2i Therapeutics in?

A2i Therapeutics operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Molecules. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals.

Where is A2i Therapeutics located?

A2i Therapeutics is based in Ilan Ramon Street 2, Ness Ziona, Israel.

View Full Profile Classic View